About Us

HemaCure is a translational stage company developing a platform technology that enables safe, nontoxic replacement of autologous CD34+ stem cells. Our platform technology offers a high degree of compatibility and versatility for cell-based therapies for the treatment of several diseases with significant unmet medical need and commercial potential.

Our lead candidate is a disease-modifying cell-based therapy for the treatment of patients with acquired, generalized Parkinson's Disease. Currently, we are developing our process to test this therapy in first-in-human trials in 2022. We have development programs for other neurological diseases such as Alzheimer's Disease, blood disorders, immune disorders, and other multi-system therapeutics including blood and immune rejuvenation.

KOL Perspectives

“In some ways this is the Neurology analog of autologous CAR T cancer therapy. Using the patient’s own cells modified to specifically target a pathological process. These approaches have completely revolutionized oncology treatments. There should be substantial interest in Neurology to try a similar approach.”

- Dr. Dana Hilt, CMO, Frequency Therapeutics, former CMO, Lysosomal Therapeutics

“I truly believe in the future value of cell and gene therapy in general and specifically think that using these tools is the only way to utilize the enormous potential of the trophic effects of GDNF in Parkinson’s Disease.”

- Prof. Geert Jan Groeneveld, Leiden University Medical Center

“Given the lack of disease-modifying treatments for neurodegenerative disorders, including Parkinson’s disease, the use of programmed macrophages to deliver therapeutic GDNF directly to affected brain areas is both creative and exciting. While the effectiveness of this approach in patients remains to be assessed, the animal data provide a convincing rationale for moving ahead with a carefully designed first in human trial.”

- Prof. Sudha Seshadri, MD, University of Texas Health, Founder and Director, Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases

“This is very ‘au courant’ to today’s molecular medicine and individualized therapy world. The adoption of specific and individualized therapy has completely transformed oncology. It would be truly wonderful if some of this could be translated to Neurology.”

- Dr. Dana Hilt, CMO, Frequency Therapeutics, former CMO, Lysosomal Therapeutics